About Lupin Pharmaceuticals Limited

Lupin Ltd. is a multinational pharmaceutical company based in Mumbai, Maharashtra, India. The company manufactures and sells a wide range of Branded and Generic Formulations, Active Pharmaceutical Ingredients (APIs), Advanced Drug Delivery Systems (ADDS) and Biotechnology products - in over 100 countries. Its major markets include USA, India, Japan, Europe, South Africa, Philippines and Australia.


Founded by Dr. Desh Bandhu Gupta (an associate professor) in 1968, the company manufactures products in therapy areas such as cardiovascular, anti-TB (world leader), anti-asthma, anti-diabetic, anti-infective, gastro-intestinal (GI), central nervous system (CNS), gynecology, etc.


As of 31st March 2015, the company was ranked:


  • the 3rd largest pharmaceutical company in India by revenues
  • the 6th largest pharmaceutical player in the US by prescription
  • the 7th largest generic pharmaceutical company globally by market capitalization
  • the 10th largest generic pharmaceutical company globally by sales (Bloomberg, June 2015)


About 45% of Lupin's sales during the fiscal year 2015 were from the United States, its largest market, and 24% from India, its second largest market.


The company is working to improve its supplies to Japan, the world's 2nd largest pharmaceuticals market, where it is already the 8th largest generic player. In the fiscal year 2016, the company plans to set up a new manufacturing facility for oral solids in Japan, and a dedicated Japan block in Goa.


Lupin Pharmaceutical Ltd. is listed on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE), including S&P Bombay Stock Exchange Sensitive Index (S&P BSE SENSEX).


  1. Lupin Ltd. at-a-glance




    US FDA, World Health Organization, MHRA (UK), TGA (Australia), MHLW (Japan), ANVISA (Brazil) and MCC (South Africa), etc.

    Turnover (year ended 31 March, 2015)

    $2.06 billion

    Markets Served


    Average Employee Age

    31 years

    Manufacturing Facilities


    Patents filed till date




  3. History of Lupin Pharmaceuticals Limited

    Lupin Ltd. was India's 3rd largest pharmaceutical company by revenues (as of 31st March, 2015) and the 10th largest generic pharmaceutical company globally by sales (Bloomberg, June 2015).


    The company gained recognition after it became one of the world's largest manufacturers of the anti-tuberculosis drug - where it holds a global leadership position, and is a significant player in the cardiovascular, anti-diabetic, anti-asthma, central nervous system (CNS), gastro-intestinal (GI) and anti-infective segment.


    In fiscal year 2015, the company had:

    • 13 manufacturing facilities in India, Japan & Mexico
    • Invested 8.9% of net sales on R&D
    • Filed 435 patent applications including 97 new inventions
    • Received approvals for:
      • 12 formulations patents
      • 6 API patents
      • 1 Biotech patent
      • 3 NCE patents

  5. Milestones


    • 1968 - Starts business
    • 1972 - Lupin Laboratories Pvt. Ltd. is incorporated
    • 1980 - Commissions a formulations plant and an R&D Centre at Aurangabad
    • 1981 - Starts manufacturing Ethambutol
    • 1987 - 2 plants go on-stream
      - Cephalexin Plant at Mandideep
      - 7 ADCA plant at Ankleshwar
    • 1988 - Dr. Desh Bandhu Gupta founds the The Lupin Human Welfare and Research Foundation (LHWRF) to provide an alternative, sustainable and replicable model of rural development
    • 1989 - Establishes a joint venture in Thailand - Lupin Chemicals (Thailand) Ltd.
    • 1991 - Starts producing injectable cephalosporin (bulk and dosages) at Mandideep
    • 1992 - 1994
      - Establishes fermentation plant at Tarapur, Maharashtra
      - Establishes sterile plant for injectable cephalosporins (bulk) at Mandideep
      - Raises money through IPOs (1993-94) via Lupin Laboratories Ltd. and Lupin Chemicals Ltd.
      - Wins FICCI award for contribution towards rural development
    • 1996 - Receives
      - Best Exporter award from Government of India
      - ICMA Technology award for injectable Cephalosporins
    • 1997
      • Obtains UK MCA approval for injectable Cephalosporins dosages plant at Mandideep
      • Upgrades formulations facility at Aurangabad
      • Receives US FDA approval for 3 plants
        - Cefaclor at Mandideep
        - 7 ACCA at Ankleshwar
        - Rifampicin at Tarapur
      • Wins FICCI award for contribution towards rural development
    • 1999 - Obtains UK MCA approval for injectable cephalosporin bulk active plant at Mandideep
    • 2000
      - Receives US FDA approval for its Cefotaxime facility
      - Commences R&D Centre at Pune
    • 2001
      - Becomes the only Asian pharmaceutical company to receive US FDA approvals for its sterile cephalosporin facility
      - Commissions US FDA approvable oral cephalosporin bulk active plant and an R&D Centre at Pune
      - Starts supplying Cephalosporin bulk actives to alliance partners in the US
      - Amalgamates Lupin Laboratories Ltd. with Lupin Chemicals Ltd. (whose name was changed to Lupin Ltd.)
    • 2002
      - Exports to advanced markets cross INR 1000 mn
      - Exports rise 33% year-over-year (as a % of total revenue)
      - Patent filings cross 100
      - Files 5 ANDAs
      - Commissions new anti-TB facility at Aurangabad
      - Rablet is rated the second best launch of FY 2002-03 (ORG-Marg)
    • 2003
      - Obtains US FDA approval for oral Cefaclor injectible Plant at Mandideep
      - Forms Lupin Pharmaceuticals Inc. USA for trading, marketing and developmental activities in the US
    • 2004 - Receives WHO approval for formulation plants at Goa and Aurangabad
    • 2005
      - Implements maiden employees stock option plan
      - Receives US FDA and MHRA (UK) approval for Goa
    • 2006
      - Sets up a new facility at Jammu
      - Issues maiden bonus shares at a 1:1 ratio
      - Launches maiden issue of Foreign Currency Convertible Bonds (FCCB) aggregating US $100 mn, listed on Singapore Stock Exchange
      - Receives US FDA approval for its new Lovastatin plant at Tarapur was approved by the US FDA
    • 2007
      - Acquires Vadodara based Rubamin Laboratories Ltd (renamed Novodigm Ltd.)
      - Acquires Kyowa Pharmaceutical Industry Company Limited, Japan's leading generic company
      - Starts commercial production at the newly finished dosage facility at Jammu
      - Receives the Best New Manufacturer of The Year award from Amerisource Bergen
    • 2008
      - Expands product basket in Japan-Kyowa and receives 10 product approvals from Ministry of Health & Labour Welfare, Japan
      - Acquires Hormosan Pharma GmbH, a generic Company in Germany
      - Acquires stake in Generic Health Pty Ltd., in Australia
      - Acquires major stake in Pharma Dynamics in South Africa
    • 2009 - Acquires majority stake in Multicare Pharmaceuticals Philippines Inc.
    • 2011
      - Acquires I'rom Pharmaceuticals through its Japanese subsidiary
      - Enters into Joint Development Agreement with Medicis
      - Acquires worldwide rights for Goanna®
    • 2013 - Inaugurates new plant at Nagpur
    • 2014
      - Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic Company; enters the Latin American Market
      - Acquires Nanomi B.V; enters the complex injectables space
    • 2015
      - Inaugurates a Centre of Excellence for Inhalation Research in Coral Springs, Florida
      - Acquires specialty product portfolio of Temmler Pharma GmbH & Co. in Germany
      - Acquires Gavis Pharma in New Jersey
      - Acquires Biocom in Russia
      - Acquires Medquimica in Brazil
      - Completes the acquisition of Pharma Dynamics in South Africa




  • Founder & Chairman: Dr. Desh Bandhu Gupta
  • Vice Chairman : Dr. Kamal K Sharma
  • Chief Executive Officer: Ms. Vinita Gupta
  • Managing Director: Mr. Nilesh Gupta
  • Independent Directors: Dr. Vijay Kelkar, Mr. RA Shah, Mr. Richard Zahn, Dr. KU Mada, Mr. Dileep C Choksi





159, C.S.T. Road, Kalina
Santacruz (East), Mumbai - 400 098
Tel:+ 91 22 6640 2323
Fax:+ 91 22 2652 8806
Email: info@lupin.com


Aurobindo Pharma Limited
Laxmi Towers, 'B' Wing
Bandra Kurla Complex
Bandra (East),
Mumbai - 400 051
Tel: + 91 22 6640 2222
Fax: + 91 22 6640 2130


Mr. Pradeep Bhagwat
General Manager, Investors' Services
Email: pradeepbhagwat@lupin.com

Mr. Alpesh Dalal
Head - Investor Relations
Email: alpeshdalal@lupin.com


Mr. Shamsher Gorawara
Head, Corporate Communications
Email: shamshergorawara@lupin.com


* Indicates mandatory field.
Please wait while comments are being sent...